Kisplyx (Lenvatinib)

• Lenvatinib acts on multiple kinase‑driven pathways involved in tumor growth and angiogenesis, providing therapeutic benefit across several solid‑tumour indications, particularly in advanced disease settings where conventional therapies have limited efficacy.
• Differentiated thyroid cancer: improves progression‑free survival in patients with radioactive iodine‑refractory disease.
• Renal cell carcinoma: extends overall survival in advanced clear‑cell RCC.
• Hepatocellular carcinoma: delays tumor progression in unresectable disease.
• Endometrial carcinoma: enhances response rates when combined with pembrolizumab in advanced cases.

• Lenvatinib inhibits multiple receptor tyrosine kinases, including VEGFR 1‑3, FGFR 1‑4, PDGFRα, RET and KIT. By blocking these signaling pathways, the drug reduces tumor angiogenesis, impairs fibroblast growth factor–driven proliferation, and interferes with oncogenic driver mutations, leading to decreased tumor vascularization and cell growth. The inhibition is dose‑dependent and results in sustained suppression of downstream MAPK and PI3K‑AKT cascades, contributing to antitumor activity.

Lenvatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Hypertension: elevated blood pressure often requiring antihypertensive therapy.
• Diarrhea: mild to moderate gastrointestinal upset.
• Fatigue: generalized tiredness affecting daily activities.
• Nausea: occasional feeling of sickness, may be managed with antiemetics.
• Proteinuria: presence of protein in urine indicating renal impact.
• Stomatitis: inflammation of the mouth lining.

Serious or Rare Side Effects

• Hepatotoxicity: significant elevation of liver enzymes or liver failure.
• Cardiac dysfunction: heart failure or reduced ejection fraction.
• Arterial thromboembolism: risk of stroke or myocardial infarction.
• Severe hemorrhage: bleeding events requiring medical attention.
• Renal failure: acute kidney injury in susceptible patients.
• Fatal events: rare cases of treatment‑related mortality.

Before initiating Lenvatinib therapy, clinicians should evaluate several safety parameters and monitor patients regularly.

• Blood pressure monitoring: check baseline and periodic readings to manage hypertension.
• Liver function tests: assess ALT, AST, bilirubin before and during treatment.
• Renal function assessment: evaluate creatinine clearance to adjust dosing if needed.
• Cardiac evaluation: perform echocardiogram to detect potential heart failure.
• Pregnancy and lactation: avoid use; contraindicated due to potential fetal harm.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Lenvatinib may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may reduce plasma concentrations of Lenvatinib.
• Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with Lenvatinib.
• Concomitant VEGF inhibitors: additive risk of hypertension and proteinuria.
• Other anti‑angiogenic agents: may amplify hypertension and proteinuria.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., ketoconazole): may increase Lenvatinib exposure.
• Diuretics: may exacerbate hypertension or electrolyte disturbances.
• Immunosuppressants (e.g., cyclosporine): potential for altered drug levels.
• Proton pump inhibitors: may affect absorption, monitor plasma levels.